The 3D bioproduction platform
StemInov’s platform is engineered to solve the core limitations of conventional MSCs
A proprietary
3D bioproduction process addressing the core MSC limitations
3D
- 3 liters
- Single use bioreactors
- GMP like
2 Patents
High reproducibility
Ensuring batch-to-batch consistency
Manufacturing scalability
3D bioreactors expand to clinical-grade volumes and commercialization
Preserved cell potency
Therapeutic cell activity preserved, comparable to native cells, high viability
Low immunogenicity
A low immune response, allowing repeat dosing
StemInov’s 3D bioproduction platform preserves cell potency compared to 2D
Preserved cell potency
Minimal manipulation — one detachment step (trypsinization), keeping cells stress-free, preserving potency
—
High-potency, high-quality cells, ready to use
Stronger expression of key immunomodulatory and functional MSC markers vs conventional 2D
Higher expression of cell migration biomarker (CXCR4) in 3D vs. 2D, supporting enhanced MSC homing to damaged lung tissue
StemInov’s 3D bioproduction platform enables low immunogenicity and very good cell viability
Low immunogenicity
Low immune response, allowing repeat dosing and off-the-shelf treatments
Immune-tolerance signal — WJ-MSCs strongly express HLA-G6, a well- documented driver of low immunogenicity
No immune-trigger marker — WJ-MSCs lack HLA-DR (marker provokingimmune rejection)
94% cell viability
Cells staying “young” — under 15% senescent cells even after 30 population doublings
Applications & clinical landscape
StemInov platform expands the use of stem cell-based solutions and opens ways for partnering
MSCs’ properties can treat a wide range of diseases
>200 clinical trials in MSC funded by industry players
Increasing prevalence of chronic diseases, suitable for the treatment with MSCs
Partnering & licensing
StemInov can monetize its MSC platform through R&D collaborations, CDMO partnerships & out-licensing agreements
R&D collaborations
Opportunity to partner on non-strategic applications
CDMO partnerships
Opportunity to manufacture WJ-MSCs for third-party developers
Out-licensing agreements
Opportunity to monetize development of WJ-MSC in additional indications
Partners
R&D
Support
Labels
